Regional development of healthcare partnerships to support patients receiving oral therapy: PACTO 34 (notice n° 177757)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02365cam a2200277 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112040737.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Del Rio, Maguy |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Regional development of healthcare partnerships to support patients receiving oral therapy: PACTO 34 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 72 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Oral therapy (OT) is one of the most advanced therapies available in cancer treatment. However, patients need to be treated on an outpatient basis, which calls for a high level of autonomy. With the financial support of the Occitanie Regional Health Agency (ARS Occitanie), the Montpellier Cancer Institute (ICM) has set up a patient support program involving accompanying patient partners (APPs). The aims of this program are: to enhance current outpatient care for the patient, reduce social withdrawal, and assess the added value of this additional support from APPs. Two APPs were recruited, trained, and included as fully-fledged members of the OT Care Team. Implemented in January 2023, initial feedback shows that over 50 percent of patients accepted the peer support offered and felt understood, reassured, confident, and morally supported by APPs. Another noted benefit of the program is how easily patients can communicate with the OT Care Team. One expected impact of this support is to improve treatment compliance and detect toxicity at an earlier stage. Evaluation of this support program, planned over three years, will take into account the advantages for patients, the care team, and APPs themselves, but will also aim to identify a medical-economic model ensuring the long-term viability of the scheme and facilitating its rollout in other healthcare areas. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Leenhardt, Fanny |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Le Turioner, Delphine |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Claisse, Emilie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Levy, Alexia |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fuzellier, Emilie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Davy, Stéphanie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Jouvet, François |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Viala, Marie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Boiseau, Anne |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Guillaumon, Cédric |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 10 | 1 | 2024-02-26 | p. 35-39 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2024-1-page-35?lang=en">https://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2024-1-page-35?lang=en</a> |
Pas d'exemplaire disponible.
Réseaux sociaux